Dr. Sarah B. Mulkey

Avindra Nath is a Neurologist in Baltimore, Maryland. Dr. Nath is rated as a Distinguished provider by MediFind in the treatment of Severe Acute Respiratory Syndrome (SARS). His top areas of expertise are Progressive Multifocal Leukoencephalopathy, Encephalitis, CACH Syndrome, and Stroke.

A leading expert on brain injury, Dr. Daniel F. Hanley has been a professor of neurology, neurosurgery, and anesthesiology/critical care medicine at the Johns Hopkins University School of Medicine since 1996 and was named the Jeffrey and Harriet Legum Chair of Acute Care Neurology. Dr. Hanley founded and directed the Johns Hopkins Neurocritical Care Unit, one of the first critical care units dedicated solely to neurosurgical and neurological patients. Subsequently, in 1999, he founded and continues to direct the BIOS Clinical Trials Coordinating Center (BIOS CTCC), formerly known as the Division of Brain Injury Outcomes. Under Dr. Hanley’s leadership, BIOS CTCC, an academic contract research organization based at Johns Hopkins, has organized and completed more than 20 large clinical trials. He has been awarded over 70 clinical and basic research grants, predominantly from the National Institutes of Health and the FDA Orphan Products Grants Program. Dr. Hanley’s 40-year career in medicine has focused on clinical trial design, the organization and interpretation of drug and device trials, the development of strategic research plans, and FDA regulatory compliance. He has led international, NIH-sponsored trials including the MISTIE III and CLEAR III trials investigating minimally invasive neurosurgical techniques to treat hemorrhagic stroke. As principal investigator for the National Center for Advancing Translational Sciences (NCATS) Johns Hopkins Trial Innovation Center, Dr. Hanley leads collaborative efforts to advance education and therapeutics through innovative CTSA clinical trials. Currently, Dr. Hanley is the PI or multi-PI for several ongoing trials. These include a multisite phase 2/3 randomized controlled dementia prevention trial (MAP), a large multicenter clinical trial involving automated monitoring of atrial fibrillation (REACT AF), and a first-in-patient phase 2a biomarker and edema attenuation in intracerebral hemorrhage trial (BEACH). Dr. Hanley has published over 400 peer-reviewed articles and book chapters, received the Humboldt Research Prize for accomplishments in brain injury research, and mentored nearly 100 researchers. His trainees, which include a large number of trialists, have led 25 brain intensive care units, and over 40 have been named full professors, program leaders, or department chairs. He has served on public boards including the American Academy of Neurology, National Stroke Association, and NIH National Institute of Nursing Research. Dr. Hanley is rated as a Distinguished provider by MediFind in the treatment of Severe Acute Respiratory Syndrome (SARS). His top areas of expertise are Stroke, Hydrocephalus, Vertigo, Severe Acute Respiratory Syndrome (SARS), and Thrombectomy.

Brenda Banwell is the director of the Department of Pediatrics, as well as pediatrician-in-chief and co-director of Johns Hopkins Children’s Center, where she helps manage the hospital’s many clinical and research centers. Dr. Banwell is a renowned expert in the research and treatment of pediatric multiple sclerosis (MS) and other neuroimmune disorders. She specializes in and studies the use of neuroimaging to assess the clinical and cognitive impact of the conditions, as well as the function of the immune system in children with these disorders. She also created a standardized clinical care algorithm and clinical database in order to evaluate the clinical impact of MS. Dr. Banwell has published more than 250 manuscripts in high-impact journals, along with over 25 book chapters. In addition, she has over 200 national and international invited lectureships and visiting professorships. An advocate for pediatric multiple sclerosis needs and research, Dr. Banwell serves as chair of the International Medical and Scientific Board of the Multiple Sclerosis International Federation, and the Myelin Oligodendrocyte Glycoprotein Antibody–Associated Disease (MOGAD) International Research Consortium. She is also chair of the pediatric committee of the National Institutes of Health NeuroNEXT program, which conducts studies on treatments for neurological diseases through academic, private, and industry collaborations. Dr. Banwell currently serves as past-chair of the International Pediatric Multiple Sclerosis Study Group, Dr. Banwell earned her medical degree from the University of Western Ontario. She later completed a residency in pediatrics at the University of Western Ontario-Children's Hospital of Western Ontario and a second residency in pediatric neurology at University of Toronto – The Hospital for Sick Children. Her residencies were followed by a fellowship in neuromuscular research at Mayo Clinic. Dr. Banwell is rated as an Elite provider by MediFind in the treatment of Severe Acute Respiratory Syndrome (SARS). Her top areas of expertise are Multiple Sclerosis (MS), CACH Syndrome, Optic Neuritis, and Transverse Myelitis.